logo
MicroCloud Hologram Inc. Develops a Noise-Resistant Deep Quantum Neural Network (DQNN) Architecture to Optimize Training Efficiency for Quantum Learning Tasks

MicroCloud Hologram Inc. Develops a Noise-Resistant Deep Quantum Neural Network (DQNN) Architecture to Optimize Training Efficiency for Quantum Learning Tasks

Yahooa day ago

SHENZHEN, China, June 10, 2025 (GLOBE NEWSWIRE) -- MicroCloud Hologram Inc. (NASDAQ: HOLO), ('HOLO' or the "Company"), a technology service provider, announced the development of a noise-resistant Deep Quantum Neural Network (DQNN) architecture aimed at achieving universal quantum computing and optimizing the training efficiency of quantum learning tasks. This innovation is not merely a quantum simulation of traditional neural networks but a deep quantum learning framework capable of processing real quantum data. By reducing quantum resource demands and enhancing training stability, this architecture lays the foundation for future Quantum Artificial Intelligence (Quantum AI) applications.
Deep Neural Networks (DNNs) have demonstrated remarkable capabilities in various fields such as computer vision, natural language processing, and autonomous driving. However, with the rapid advancement of quantum computing, the scientific community is actively exploring how to leverage quantum computing to enhance the performance of machine learning models. Traditional quantum neural networks often borrow structures from classical neural networks and simulate classical weight update mechanisms using Parameterized Quantum Circuits (PQCs). However, these approaches are typically constrained by noise effects, and training complexity increases significantly as network depth grows.
Against this backdrop, HOLO has proposed a Deep Quantum Neural Network architecture that uses qubits as neurons and arbitrary unitary operations as perceptrons. This architecture not only supports efficient hierarchical training but also effectively reduces quantum errors, enabling robust learning from noisy data. This innovation overcomes the previous bottleneck of limited depth scalability in quantum neural networks, opening new opportunities for quantum artificial intelligence applications.
The core of this architecture lies in the construction of quantum neurons. Unlike classical neural networks, which use scalar values to represent neuron activation states, the neurons in a quantum neural network are represented by quantum states. These quantum states can store richer information and enhance computational power through mechanisms such as quantum superposition and entanglement.
Each neuron updates its state through unitary operations, analogous to activation functions in classical neural networks. These unitary operations preserve the normalization property of quantum states and ensure that information is not lost during computation. This perceptron design endows the quantum neural network with powerful expressive capabilities, enabling it to adapt to complex quantum data patterns while reducing computational errors.
To enable efficient training of the quantum neural network, HOLO employs an optimization strategy based on fidelity. Fidelity is a key metric that measures the similarity between two quantum states and is widely used in quantum information processing. During training, the quantum neural network aims to maximize the fidelity between the current state and the desired target state, rather than minimizing a loss function as in classical neural networks. This strategy allows the quantum neural network to converge to an optimal solution in fewer training steps, significantly reducing the quantum resources required for training.
Moreover, this optimization approach exhibits strong robustness, effectively handling the inherent noise and errors in quantum systems. In quantum hardware experiments, HOLO validated the effectiveness of this optimization method and found that it maintains stable learning performance even in noisy environments. This characteristic makes the architecture practically viable on current Noisy Intermediate-Scale Quantum (NISQ) computers.
While the depth expansion of classical neural networks typically leads to an exponential increase in parameters, quantum neural networks face challenges related to the number of qubits and the complexity of entanglement during expansion. To address this, the architecture optimizes the quantum state encoding method, ensuring that the required number of qubits scales only with the network's width rather than its depth.
This innovative design implies that even as the neural network becomes very deep, the required qubit resources remain within a manageable range, thereby reducing hardware demands. This feature enables the deep quantum neural network to be trained on existing quantum processors and provides a feasible path for the realization of large-scale quantum machine learning models in the future.
HOLO conducted several benchmark tests. One key task involved learning unknown quantum operations, where the quantum neural network was trained to predict how unknown quantum operations affect different input states. The results demonstrated that this architecture not only accurately learns target quantum operations but also exhibits excellent generalization capabilities. This means that even with limited training data, the quantum neural network can still infer reasonable quantum mapping relationships. Furthermore, even when the training data contains some noise, the network maintains stable learning performance, further proving its robustness in noisy environments.
As quantum computing technology continues to advance, the practical application prospects of deep quantum neural networks are becoming increasingly broad. The development of HOLO's architecture not only advances the field of quantum machine learning but also opens new possibilities for various industries. HOLO plans to further optimize this architecture and explore its potential applications on larger-scale quantum computers. In the future, with the development of quantum hardware, deep quantum neural networks are expected to play a critical role in more real-world scenarios, paving new paths for the integration of artificial intelligence and quantum computing.
HOLO has successfully developed a noise-resistant deep quantum neural network architecture that overcomes the limitations of traditional quantum neural networks, achieving efficient hierarchical training and quantum computing optimization. By using fidelity as the optimization target, this network reduces the demand for computational resources while maintaining robustness against noisy data. Experimental results have demonstrated its excellent generalization capabilities and practical feasibility, laying the foundation for the future development of quantum artificial intelligence. As quantum computing technology continues to mature, this innovative architecture is poised to play a significant role in multiple industries, ushering artificial intelligence into a new era of quantum computing.
About MicroCloud Hologram Inc.
MicroCloud is committed to providing leading holographic technology services to its customers worldwide. MicroCloud's holographic technology services include high-precision holographic light detection and ranging ('LiDAR') solutions, based on holographic technology, exclusive holographic LiDAR point cloud algorithms architecture design, breakthrough technical holographic imaging solutions, holographic LiDAR sensor chip design and holographic vehicle intelligent vision technology to service customers that provide reliable holographic advanced driver assistance systems ('ADAS'). MicroCloud also provides holographic digital twin technology services for customers and has built a proprietary holographic digital twin technology resource library. MicroCloud's holographic digital twin technology resource library captures shapes and objects in 3D holographic form by utilizing a combination of MicroCloud's holographic digital twin software, digital content, spatial data-driven data science, holographic digital cloud algorithm, and holographic 3D capture technology. For more information, please visit http://ir.mcholo.com/
Safe Harbor Statement
This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as 'may,' 'will,' 'intend,' 'should,' 'believe,' 'expect,' 'anticipate,' 'project,' 'estimate,' or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the following: the Company's goals and strategies; the Company's future business development; product and service demand and acceptance; changes in technology; economic conditions; reputation and brand; the impact of competition and pricing; government regulations; fluctuations in general economic; financial condition and results of operations; the expected growth of the holographic industry and business conditions in China and the international markets the Company plans to serve and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the Securities and Exchange Commission ('SEC'), including the Company's most recently filed Annual Report on Form 10-K and current report on Form 6-K and its subsequent filings. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.
ContactsMicroCloud Hologram Inc.Email: IR@mcvrar.com

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Honeywell Finalizes Sundyne Acquisition to Boost Its Process Industry Strength
Honeywell Finalizes Sundyne Acquisition to Boost Its Process Industry Strength

Yahoo

time21 minutes ago

  • Yahoo

Honeywell Finalizes Sundyne Acquisition to Boost Its Process Industry Strength

Honeywell International Inc. (NASDAQ:HON) is one of the best Dow stocks to invest in. On June 9, the company announced that it had finalized its $2.16 billion all-cash acquisition of Sundyne from private equity firm Warburg Pincus. Sundyne, known for its advanced pumps and gas compressors used in process industries, is expected to contribute immediately to Honeywell International Inc. (NASDAQ:HON)'s revenue growth, segment margins, and adjusted earnings per share during the first full year of ownership. Sundyne brings strong customer relationships and top-tier technology, which are expected to enhance Honeywell UOP's presence in areas like refining, petrochemicals, LNG, and clean energy. Integrated with the Honeywell Forge platform, the combined offering strengthens Honeywell's position in the energy transition by providing a comprehensive, scalable solution. This acquisition comes on the heels of Honeywell International Inc. (NASDAQ:HON)'s recent announcement to spin off its Aerospace Technologies and Solstice Advanced Materials units, moves aimed at creating three separate publicly traded companies, each with focused strategies and growth opportunities. Since December 2023, Honeywell has pursued several strategic initiatives to boost organic growth and streamline its operations, including $13.5 billion in value-enhancing acquisitions. The company operates globally across a wide range of industries. HON has surged by over 7% in the past 12 months. While we acknowledge the potential of HON as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

How major US stock indexes fared Wednesday, 6/11/2025
How major US stock indexes fared Wednesday, 6/11/2025

Yahoo

time25 minutes ago

  • Yahoo

How major US stock indexes fared Wednesday, 6/11/2025

Wall Street's rally stalled after stocks climbed back within 2% of their all-time high. The S&P 500 slipped 0.3% Wednesday, marking its first drop in four days. The Dow Jones Industrial Average ended little changed, and the Nasdaq composite lost 0.5%. The action was stronger in the bond market, where Treasury yields eased after a report showed inflation ticked up by less last month than economists expected. That raised expectations for the Federal Reserve to cut interest rates later this year. Markets didn't react much to the conclusion of two days of trade talks between the U.S. and China. On Wednesday: The S&P 500 fell 16.57 points, or 0.3%, to 6,022.24. The Dow Jones Industrial Average fell 1.10 points, or less than 0.1%, to 42,865.77. The Nasdaq composite fell 99.11 points, or 0.5%, to 19,615.88. The Russell 2000 index of smaller companies fell 8.17 points, or 0.4%, to 2,148.23. For the week: The S&P 500 is up 21.88 points, or 0.4%. The Dow is up 102.90 points, or 0.2%. The Nasdaq is up 85.92 points, or 0.4%. The Russell 2000 is up 15.99 points, or 0.7%. For the year: The S&P 500 is up 140.61 points, or 2.4%. The Dow is up 321.55 points, or 0.8%. The Nasdaq is up 305.08 points, or 1.6%. The Russell 2000 is down 81.92 points, or 3.7%. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

Allarity Therapeutics Announces Changes to Board of Directors
Allarity Therapeutics Announces Changes to Board of Directors

Yahoo

time30 minutes ago

  • Yahoo

Allarity Therapeutics Announces Changes to Board of Directors

TARPON SPRINGS, Fla., June 11, 2025 -- Allarity Therapeutics, Inc. ('Allarity' or the 'Company') (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor—as a personalized cancer treatment using its proprietary, drug-specific Drug Response Predictor (DRP®) patient selection technology—today announced that Jesper Høiland has been appointed to join the Company's Board of Directors. He will be replacing Joseph Vazzano, who will resign from the Board effective on June 30, 2025, following his valuable contributions to Allarity's development over the past two years. Mr. Høiland is already well-acquainted with Allarity's mission and operations, having served as a strategic consultant to the Company since October 2024. Jesper Høiland is a highly respected industry leader with more than 30 years of experience in global pharmaceutical commercialization and executive leadership. He previously served as President and EVP of Novo Nordisk's U.S. operations, where he led major product launches, pricing strategies, and infrastructure expansion. In addition, he held senior executive roles as President and CEO of Radius Health and as Global Commercial Officer at Ascendis Pharma. Mr. Høiland currently serves as Chairman of SciBase Holding AB and is a board member of ALK-Abello A/S and Flen Health SA. 'We are pleased to welcome Jesper Høiland to the Allarity Board during a period of growing clinical momentum,' said Jerry McLaughlin, Chairman of the Board of Directors at Allarity Therapeutics. 'On behalf of the entire Board, I would also like to thank Joseph Vazzano for his contributions to Allarity. His financial expertise and thoughtful guidance helped strengthen our governance and operational focus during a critical time. We are grateful for his service and wish him the very best in his ongoing endeavors.' Thomas Jensen, CEO of Allarity Therapeutics, added: 'Since Jesper started working with us in his consultancy capacity, I have several times benefited from his experience and strategic advice. His deep understanding of how to prepare for the commercialization phase of an investigational drug, his extensive global network—built over decades at Novo Nordisk—and his proven leadership during periods of strategic transition at Radius Health will certainly be valuable to Allarity. It is very positive that he will now be even more closely engaged with the Company, as we prepare for the next phases of clinical development and potential later commercialization of stenoparib.' About StenoparibStenoparib is an orally available, small-molecule dual-targeted inhibitor of PARP1/2 and tankyrase 1/2. At present, tankyrases are attracting significant attention as emerging therapeutic targets for cancer, principally due to their role in regulating the WNT signaling pathway. Aberrant WNT/β-catenin signaling has been implicated in the development and progression of numerous cancers. By inhibiting PARP and blocking WNT pathway activation, stenoparib's unique therapeutic action shows potential as a promising therapeutic for many cancer types, including ovarian cancer. Allarity has secured exclusive global rights for the development and commercialization of stenoparib, which was originally developed by Eisai Co. Ltd. and was formerly known under the names E7449 and the Drug Response Predictor – DRP® Companion DiagnosticAllarity uses its drug-specific DRP® to select those patients who, by the gene expression signature of their cancer, may have a high likelihood of benefiting from a specific drug. By screening patients before treatment, and only treating those patients with a sufficiently high, drug-specific DRP score, the therapeutic benefit rate may be enhanced. The DRP method builds on the comparison of sensitive vs. resistant human cancer cell lines, including transcriptomic information from cell lines, combined with clinical tumor biology filters and prior clinical trial outcomes. DRP is based on messenger RNA expression profiles from patient biopsies. The DRP® platform has shown an ability to provide a statistically significant prediction of the clinical outcome from drug treatment in cancer patients across dozens of clinical studies (both retrospective and prospective). The DRP platform, which may be useful in all cancer types and is patented for dozens of anti-cancer drugs, has been extensively published in the peer-reviewed Allarity TherapeuticsAllarity Therapeutics, Inc. (NASDAQ: ALLR) is a clinical-stage biopharmaceutical company dedicated to developing personalized cancer treatments. The Company is focused on development of stenoparib, a novel PARP/tankyrase inhibitor for advanced ovarian cancer patients, using its DRP® technology to develop a companion diagnostic that can be used to select those patients expected to derive the greatest clinical benefit from stenoparib. Allarity is headquartered in the U.S., with a research facility in Denmark, and is committed to addressing significant unmet medical needs in cancer treatment. For more information, visit Follow Allarity on Social MediaLinkedIn: Forward-Looking Statements This press release contains 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements provide the Company's current expectations or forecasts of future events. The words 'anticipates,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intends,' 'may,' 'might,' 'plan,' 'possible,' 'potential,' 'predicts,' 'project,' 'should,' 'would' and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, statements regarding the anticipated contributions of Jesper Høiland to Allarity's strategic direction; expectations about the Company's clinical and commercial development of stenoparib; the Company's ability to benefit from enhanced leadership and governance; and the potential future impact of board changes on corporate strategy and stakeholder value. Any forward-looking statements in this press release are based on management's current expectations of future events and are subject to multiple risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to risks related to changes in leadership not yielding expected outcomes; uncertainties around clinical development timelines; risks that clinical data may not support regulatory approval or commercial viability; and the general risks associated with operating a clinical-stage biopharmaceutical company. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled 'Risk Factors' in our Form 10-K annual report filed with the Securities and Exchange Commission (the 'SEC') on March 31, 2025, available at the SEC's website at and as well as discussions of potential risks, uncertainties and other important factors in the Company's subsequent filings with the SEC. All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information unless required by law. ### Company Contact: investorrelations@ Media Contact: Thomas Pedersen Carrotize PR & Communications +45 6062 9390 tsp@ Attachment Allarity Therapeutics Press Release - Announces Changes to Board of DirectorsError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store